MedTrace Logo

Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke

NCT00815763 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2008-12-30

No results posted yet for this study

Summary

The purpose of this phase 3 study is to validate the efficacy and safety of ginsenoside-Rd for acute ischemic stroke.

Conditions

Interventions

DRUG

ginsenoside-Rd

infusion ginsenoside-Rd 20 mg once a day and continued for 14 day

DRUG

placebo

infusion placebo once a day and continued for 14 day

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Gang Zhao, MD · the Department of Neurology , Xijing Hospital

  • Xuedong Liu, MD · the Department of Neurology, Xijing Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-06-30
Completion
2008-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00815763 on ClinicalTrials.gov